Mezavant

Mesalazine, the active ingredient in Mezavant, is an aminosalicylate presented as a tablet for oral use. It is used to maintain remission in ulcerative colitis patients.\n\nGNH India supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant is an aminosalicylate that acts on inflammatory bowel disease, particularly ulcerative colitis.\n\nUlcerative colitis (induction of remission): reduces colonic inflammation to achieve symptom control.\nUlcerative colitis (maintenance of remission): helps sustain disease remission and prevent relapse.\nUlcerative colitis (mild to moderate disease): provides anti‑inflammatory effect throughout the colon.

Adverse reactions may occur with any medication and should be monitored.\n\nCommon Side Effects:\n- Nausea\n- Headache\n- Abdominal pain\n- Diarrhea\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., anaphylaxis)\n- Blood dyscrasias such as neutropenia or agranulocytosis\n- Interstitial nephritis or other kidney inflammation

Safety considerations are important when prescribing Mezavant.\n\nMonitor renal function: assess serum creatinine before and during therapy.\nAssess hepatic function: check liver enzymes periodically.\nAvoid use in patients with known hypersensitivity to mesalazine.\nUse with caution in patients with sulfonamide allergy.\nPregnancy and breastfeeding: discuss risks with healthcare provider.\nStore at ambient temperature: keep below 25 °C, protect from moisture and light.

Drug interaction potential should be reviewed before initiating therapy.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin): may increase bleeding risk.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal toxicity.\n- Methotrexate: may increase mesalazine levels and toxicity.\n\nModerate Interactions (Monitor Closely):\n- Oral corticosteroids: may increase risk of infection.\n- Diuretics: may affect renal clearance of mesalazine.